Savara Inc (NASDAQ:SVRA) has been given an average rating of “Buy” by the eight research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $26.40.
Several research analysts have weighed in on the stock. BidaskClub upgraded shares of Savara from a “sell” rating to a “hold” rating in a research report on Saturday. Roth Capital reduced their price objective on shares of Savara from $40.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, October 31st. ValuEngine cut shares of Savara from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Ladenburg Thalmann Financial Services initiated coverage on shares of Savara in a research note on Wednesday, January 3rd. They issued a “buy” rating and a $35.00 price objective for the company. Finally, Canaccord Genuity increased their price objective on shares of Savara from $18.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, October 30th.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Deutsche Bank AG grew its stake in Savara by 136,538.5% during the fourth quarter. Deutsche Bank AG now owns 17,763 shares of the company’s stock valued at $263,000 after acquiring an additional 17,750 shares in the last quarter. BlueCrest Capital Management Ltd purchased a new position in shares of Savara in the 4th quarter worth $353,000. Renaissance Technologies LLC grew its stake in shares of Savara by 260.2% in the 4th quarter. Renaissance Technologies LLC now owns 37,483 shares of the company’s stock worth $556,000 after buying an additional 27,076 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Savara in the 4th quarter worth $464,000. Finally, Geode Capital Management LLC grew its stake in shares of Savara by 271.7% in the 4th quarter. Geode Capital Management LLC now owns 153,388 shares of the company’s stock worth $2,276,000 after buying an additional 112,118 shares in the last quarter. 18.43% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/02/14/savara-inc-svra-receives-average-rating-of-buy-from-brokerages.html.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.